The mutant IDH1 inhibitor ivosidenib (approved for the treatment of AML patients with a susceptible IDH1 mutation) recently demonstrated efficacy in advanced CCA patients with an IDH1 mutation [71]. The gene discussed is IDH1; the disease is acute myeloid leukemia.